All articles tagged with #statins
New guidelines from the American College of Cardiology and other groups push for earlier attention to cholesterol—potentially starting around age 30—with clearer targets and guidance on when medications like statins may help, alongside lifestyle changes; doctors emphasize regular cholesterol screening and personalized risk assessment to reduce heart disease and stroke risk.
A multicenter prospective trial shows a retinal-imaging AI (CLAiR AI) accurately estimates 10-year ASCVD risk and could help identify patients who may benefit from lipid-lowering therapy. Among 847 participants without ASCVD, about 26% had a 10-year risk ≥7.5% (the older threshold), while the 2026 ACC/AHA PREVENT guideline lowers the threshold to 5%, potentially expanding statin eligibility. The AI achieved 91.1% sensitivity, 86.2% specificity, and ~0.96 AUC, using a standard slit-lamp camera that requires no dilation or blood draw and could be used in primary care or optometry. A larger validation is needed, and future outputs should ideally estimate actual disease risk (e.g., coronary plaque, heart attacks) beyond risk scoring.
A comprehensive look at common statin myths: large randomized trials show muscle pain is largely a nocebo effect, with true statin-related pain being rare; any diabetes risk from statins is small in absolute terms (low-dose increases ~0.12% per year, high-dose ~1.27% per year) and outweighed by big reductions in heart attacks and strokes; memory loss and liver damage are not proven causal effects and serious liver injury is extremely rare; and the greatest benefit comes from combining statins with healthy lifestyle changes. High-dose statins can lower LDL by about 50% and, when paired with lifestyle improvements, significantly reduce cardiovascular risk.
New guidelines from the ACC, AHA and other medical groups say treating high cholesterol may begin as early as age 30 for people with LDL cholesterol of 160 mg/dL or higher, a strong family history of premature heart disease, or a high 30-year cardiovascular risk, with statins plus lifestyle changes recommended to lower lifetime risk of heart attack and stroke. The article discusses what treatment might look like, why doctors urge earlier action, and what the target cholesterol levels might be, inviting readers to share questions for CNN’s Dr. Sanjay Gupta.
The AHA and ACC released the 2026 Guideline on the Management of Dyslipidemia, shifting from older risk scores to the PREVENT-ASCVD calculator to estimate 10- and 30-year ASCVD risk and emphasize lifelong heart-risk reduction through earlier screening and personalized therapy. It highlights measuring biomarkers like Lp(a) and ApoB, using coronary artery calcium scoring, and keeping statins as first-line therapy with new lipid-lowering options, advocating for earlier intervention—especially in younger adults—to reduce future heart attack and stroke risk.
New cardiovascular guidelines urge starting lipid management as early as age 30, using the PREVENT risk calculator and lower LDL targets (under 100 mg/dL for lower-risk, under 70 mg/dL for high risk, and under 55 mg/dL for very high risk). They endorse lifestyle changes, consider coronary calcium scans and biomarkers like Lp(a) and ApoB to guide therapy, and include statins and, in some cases, PCSK9 inhibitors as part of a broader prevention strategy.
A updated ACC/AHA guideline advises starting statins earlier for some adults as young as 30 with LDL ≥160 mg/dL or a high 30-year cardiovascular risk, alongside lifestyle changes. It introduces a 30-year risk calculation (PREVENT-ASCVD) to identify millions more who may benefit, with LDL targets of <100 mg/dL for most borderline/intermediate risk and <55 mg/dL for the highest risk. Treatment decisions remain clinician–patient discussions, and the guidance is supported by trial data linking longer LDL exposure reduction to lower lifetime risk.
Cancer cells release PD-L1–containing small extracellular vesicles that dampen immune attacks; the PD-L1 is sorted into these vesicles via a UBL3-driven modification at cysteine 272. Statins inhibit this modification, reducing PD-L1 packaging into vesicles and potentially enhancing responses to PD-1/PD-L1 inhibitors; early patient data show statin users have fewer PD-L1–positive vesicles, suggesting statins could be added to immunotherapy regimens to improve outcomes.
A large Lancet analysis pooling data from over 120,000 patients across 19 randomized trials finds that statins do not meaningfully increase most side effects and their cardiovascular benefits far outweigh potential risks. The piece attributes the ongoing “statin hysteria” to misinformation and celebrity/aut online narratives, noting past observational studies were misinterpreted and that skeptics persist despite this stronger evidence.
A Lancet review suggests statins are generally well tolerated, easing concerns about memory loss or sleep disturbances. About 10 million in the UK take statins, mainly for primary prevention, but benefits depend on baseline cardiovascular risk. NICE estimates that at a 10% 10-year risk, 40 strokes or heart attacks could be prevented per 1,000 people over 10 years; numbers needed to treat vary (roughly 200 people for five years to prevent one heart attack in primary prevention, about 300 to prevent one stroke, with better figures for secondary prevention). The article emphasizes that diet and lifestyle remain crucial and that statins are risk reducers, not a substitute for healthy habits. It also notes tools like QRisk to estimate personal risk, though those estimates have limitations.
A Lancet meta-analysis of 19 large randomized trials (over 122,000 participants) finds that most reported statin side effects are not supported by reliable evidence, with real adverse effects being rare (about 1% muscle symptoms; rare rhabdomyolysis; small increases in liver tests and glucose for those near diabetes thresholds). The benefits remain substantial: roughly 25% lower risk of heart attack or stroke and meaningful LDL reductions, with inexpensive generic options (~$40/year). Updated PREVENT-based risk estimates could expand who should start statins, underscoring that fears of side effects should not unduly deter appropriate preventive therapy.
A Lancet study reviewing trials of statins (over 120,000 participants) finds side effects are rare and not caused by statins, with minimal liver impact and only rare muscle or blood-sugar issues. The findings support updating patient leaflets, emphasize that statins significantly reduce LDL cholesterol and cardiovascular risk, and reinforce their role in preventing heart attacks and strokes.
A Lancet meta-analysis of 19 randomized trials involving about 124,000 participants over roughly 4.5 years finds that 62 of the 66 side-effects listed for statins have no solid evidence of being caused by the drugs; only four (liver test changes, minor liver abnormalities, urine changes, tissue swelling) have evidence supporting them. Overall, the risk of side-effects is very small and the cardiovascular benefits of statins—reducing heart attacks, strokes and cardiovascular deaths—greatly outweigh harms, prompting calls to update labeling to better reflect the evidence and reassure patients and doctors.
A new study links statin-associated muscle symptoms (SAMS) to calcium leaking into muscle cells via the RyR1 channel when statins bind to it, a finding observed in mice using cryo-EM. This mechanism explains why about 10% of statin users experience muscle pain and suggests two potential remedies: redesign statins to avoid RyR1 binding or use Rycal drugs to close the calcium gates and prevent muscle weakness.
Researchers show that statins bind to the RyR1 muscle channel and force it open, causing a toxic calcium leak that can trigger pain and damage; using cryo-electron microscopy to study atorvastatin, the team mapped a binding pattern and suggested designing safer statins that retain cholesterol-lowering effects without muscle harm.